Entera Bio Ltd.
ENTX$60M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaJERUSALEM
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 14, 2026
6wMarket Overview
Stock performance and key metrics
ENTX News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
EB612 (EBP05)
Hypoparathyroidism
EBP05
Hypoparathyroidism
EnteraBio's Oral Parathyroid Hormone (1-34)
Hypoparathyroidism
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EB612 (EBP05) | Phase 2 | Hypoparathyroidism | - | - |
EBP05 | Phase 2 | Hypoparathyroidism | - | - |
EnteraBio's Oral Parathyroid Hormone (1-34) | Phase 2 | Hypoparathyroidism | - | - |
📑
→Catalyst DossierPRO
The full research note — thesis, the if-approved scenario, financials & smart money. Compiled by CeliA.
Catalyst Verdict
Full breakdown — the signals behind the verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply